The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC).
J. A. Carter
Consultant or Advisory Role - Novartis
S. J. Snedecor
Consultant or Advisory Role - Pharmerit
S. Kaura
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
M. Botteman
Consultant or Advisory Role - Pharmerit